In addition to a fear of cancer recurrence, patients said feeling isolated was also a challenge associated with having ovarian cancer.
Patients with ovarian cancer are primarily concerned with fear of recurrence, according to new survey results published in Supportive Care in Cancer.
Although it is the third most common gynecological cancer, ovarian cancer remains underresearched, wrote the study authors, and “past studies suggest that women who present with ovarian cancer have more supportive care needs compared to women experiencing other gynecological cancers.”
In addition, although multiple options exist for treating the condition, reoccurrence can take place in up to 70% of patients.
To better understand the experiences and priorities of these patients and determine whether age influences their needs, investigators assessed survey findings from a cohort of individuals recruited by Ovarian Cancer Australia (OCA).
Woman filling online survey on her smartphone: © MclittleStock - stock.adobe.com
The survey took place in 2017 and recruited participants through a social media campaign. All individuals ranked their priorities related to living with ovarian cancer. They also endorsed which resources they had used to meet these needs, including the OCA “resilience kit,” a booklet with evidence-based information on living with the condition.
A total of 280 patients completed the survey, with the largest proportion between the ages of 60 and 69 years. Data showed that the patients’ priorities did not change with age.
An additional analyses revealed these findings:
Most patients said they lived in a major city and that they had received treatment at a private hospital. Just over 45% of patients received a diagnosis of stage III ovarian cancer. Younger patients were more likely than older patients to have an earlier-stage diagnosis.
Along with the OCA resilience kit, participants said they sought support from friends, family, and hospital treatment teams.
“Our main finding was that, in contrast to previous findings, age does not affect common concerns—fear of cancer recurrence, treatment side effects, and the uncertainties surrounding ovarian cancer,” the authors wrote.
They also note fear of cancer recurrence among women with ovarian cancer is more extreme compared with other cancers. For instance, women with breast cancer have a lower fear of cancer reoccurrence, potentially due to the fact that the average rate of reoccurrence in this cancer is 30% compared with 70% in ovarian cancer.
“Fear of cancer recurrence has been consistently associated with poorer quality of life, depression, anxiety, and impaired daily functioning,” the researchers wrote. “The long-term effect of fear of cancer recurrence is exacerbated by the inability to come to terms with the priorities that people diagnosed with cancer experience.”
Selection bias may have been present in the current study, marking a limitation. The sample also may have not been representative of all women with ovarian cancer, and few younger women participated in the survey.
Overall, more research is needed to develop interventions to address the priorities outlined in the survey, the authors concluded.
“Modes of information delivery need to consider age of the target audience—with younger women preferring to interact with technology and being more eager to receive information via mobile-app type interventions and tools compared to older women,” they wrote.
Reference
Pasvanis M, Hegarty S, Russell H, Peate M, Marino JL. Exploring the experiences and priorities of women with a diagnosis of ovarian cancer. Support Care Cancer. Published online June 30, 2023. doi:10.1007/s00520-023-07903-3
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Global Analysis Sheds Light on Women’s Cancer Trends
May 11th 2025As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.
Read More